PPA1 Activators
PPA1 activators encompass a range of chemical compounds that indirectly augment PPA1's functional activity through several cellular signaling pathways. Beta-adrenergic agonists like Isoproterenol, for instance, bind to beta-adrenergic receptors and induce a cascade that elevates intracellular cAMP. This surge in cAMP leads to the activation of protein kinase A (PKA), which is instrumental in phosphorylating target proteins that interact with and enhance PPA1 activity. Similarly, compounds like Forskolin and Dibutyryl-cAMP directly increase cAMP levels, reinforcing PKA activation and thus indirectly promoting PPA1 activity. In addition, phosphodiesterase inhibitors such as IBMX, Sildenafil, and Milrinone elevate cAMP or cGMP, further potentiating PKA or PKG pathways respectively, which are known to cross-talk with signaling pathways involving PPA1.
Compounds that modify intracellular calcium levels or kinase activity also play a significant role in modulating PPA1 activity. A23187, a calcium ionophore, increases intracellular calcium, which can trigger calcium-dependent protein kinases that subsequently interact with PPA1-related pathways. Kinase inhibitors such as Epigallocatechin gallate (EGCG) and Piceatannol alleviate negative regulation within PPA1's signaling networks, potentially enhancing PPA1's roles. Furthermore, by inhibiting PI3K and MEK with LY294002 and PD98059 respectively, the chemical landscape is altered to favor pathways that lead to PPA1 activation, highlighting the intricate balance and interconnectedness of cellular signaling and the indirect yet potent influence of these activators on PPA1's functional activity. These mechanisms collectively underscore the complexity of PPA1 regulation and the diverse array of molecules that can fine-tune its activity within the cell.
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Isoproterenol Hydrochloride | 51-30-9 | sc-202188 sc-202188A | 100 mg 500 mg | $28.00 $38.00 | 5 | |
Isoproterenol acts as a beta-adrenergic agonist. By activating beta-adrenergic receptors, it leads to an increase in intracellular cAMP, which can indirectly enhance the activity of PPA1 by promoting cAMP-dependent protein kinase A (PKA) signaling pathways that PPA1 is involved in. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
IBMX is a non-selective inhibitor of phosphodiesterases which increases intracellular cAMP levels. Elevated cAMP activates PKA, potentially upregulating PPA1 activity through phosphorylation mechanisms that are connected to the signaling cascades PPA1 participates in. | ||||||
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Forskolin activates adenylyl cyclase, thereby increasing the production of cAMP and subsequently activating PKA. PKA can then phosphorylate various proteins within the pathways that PPA1 is a part of, enhancing the functional activity of PPA1 indirectly. | ||||||
A23187 | 52665-69-7 | sc-3591 sc-3591B sc-3591A sc-3591C | 1 mg 5 mg 10 mg 25 mg | $55.00 $131.00 $203.00 $317.00 | 23 | |
A23187 is an ionophore that increases intracellular calcium levels. The influx of calcium can activate calcium-dependent signaling pathways, potentially enhancing PPA1 activity indirectly by affecting the network of proteins and signaling cascades that PPA1 is integrated within. | ||||||
Dibutyryl-cAMP | 16980-89-5 | sc-201567 sc-201567A sc-201567B sc-201567C | 20 mg 100 mg 500 mg 10 g | $47.00 $136.00 $492.00 $4552.00 | 74 | |
Dibutyryl-cAMP is a cell-permeable cAMP analog which activates PKA. PKA activation can lead to the phosphorylation of proteins within the PPA1-involved signaling pathways, thereby enhancing the functional activity of PPA1 indirectly. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $43.00 $73.00 $126.00 $243.00 $530.00 $1259.00 | 11 | |
EGCG is known to inhibit several protein kinases, thereby potentially reducing inhibitory phosphorylation events within PPA1-related pathways. This inhibition can create a favorable environment for PPA1 activation by relieving negative regulation within its signaling network. | ||||||
Piceatannol | 10083-24-6 | sc-200610 sc-200610A sc-200610B | 1 mg 5 mg 25 mg | $51.00 $71.00 $199.00 | 11 | |
Piceatannol inhibits Syk kinase, which can modulate signaling pathways that include PPA1. By inhibiting competitive signaling routes, PPA1's activity may be indirectly enhanced as the cellular signaling environment shifts to favor pathways where PPA1 is active. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor that can lead to a shift in signaling balance, favoring pathways that indirectly activate PPA1. By inhibiting PI3K, there is a potential for cross-talk with other signaling pathways that could result in the enhancement of PPA1's functional activity. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is an inhibitor of MEK, which is part of the MAPK pathway. By inhibiting MEK, PD98059 could indirectly enhance PPA1 activity by altering signaling dynamics and potentially reducing negative feedback mechanisms that limit PPA1's role in certain signaling pathways. | ||||||
Caffeine | 58-08-2 | sc-202514 sc-202514A sc-202514B sc-202514C sc-202514D | 50 g 100 g 250 g 1 kg 5 kg | $33.00 $67.00 $97.00 $192.00 $775.00 | 13 | |
Caffeine acts as a non-selective antagonist of adenosine receptors and a phosphodiesterase inhibitor, which leads to increased cAMP levels. The elevation in cAMP can enhance the activity of PKA, which may influence the activity of PPA1 through phosphorylation of proteins within its signaling pathways. | ||||||